item management s discussion and analysis of results of operations  and liquidity and capital resources a results of operations the following table summarizes the company s historical results of operations  with revenue contribution by operating segment after inter company eliminations  and consolidated costs and expenses as a percent of total net revenue 
this information should be read in conjunction with the company s financial statements and related notes 
fiscal year ended march  amount percent amount percent amount percent dollars in thousands net revenues generic products    branded products    specialty materials    contract services licenses    total net revenues    costs and expenses manufacturing costs    research and development    selling and administrative    other expense income  net a   amortization   total costs and expenses    earnings before taxes    provision for income taxes    net income a    a other income  net in fiscal and includes non recurring gains associated with million and million arbitration awards  respectively 
see note of notes to consolidated financial statements 
fiscal compared to fiscal revenues 
net revenues for fiscal increased million  or  over the prior fiscal year 
the increase in revenues was due primarily to higher sales of specialty generic and branded products 
branded product sales were up million  or  over the prior fiscal year 
the increase in sales was due to the introduction of gynazole r  a vaginal antifungal product  at the end of the first quarter of the fiscal year and higher sales of existing women s healthcare products 
these increases were partially offset by lower sales of the micro k r cardiovascular potassium supplement 
the introduction of gynazole r contributed million of incremental sales to the fiscal year on increases in market share 
since its june launch  the product has captured of total prescriptions written for vaginal antifungal creams 
existing women s healthcare products increased  or million  over last year due primarily to higher volume associated with increased market share of the precare r brand prenatal vitamin line 
including gynazole r  total sales of women s health care products increased over last year 
micro k r sales were down million compared to last year as a result of speculative customer buying during the latter half of the prior year in anticipation of a year end price increase 
specialty generic sales were up million  or  over the prior fiscal year 
the increase was due to incremental volume from new products introduced during the year million  a full year of sales of products introduced in the prior year million  net volume increases across the existing product line million  and higher pricing million primarily on cardiovascular products 
the company introduced new products during the fiscal year 
the increase in volume of the existing products was attributable to higher generic substitution rates  increased sales associated with trade shows  and price increase buy ins 
sales of specialty materials were flat for the year due to a soft market in the general industry 
contract services and licensing revenues declined 
million  or  due to lower contract manufacturing volume  reflecting a smaller customer base as the company has purposefully de emphasized lower margin contract manufacturing in its business strategy 
while the company anticipates continued overall growth in sales of the products it markets  there are no assurances that the annual percentage rate of sales growth will continue at past levels 
costs and expenses 
manufacturing costs as a percentage of revenue declined from to due to favorable product mix and lower costs within the specialty generic line  and higher pricing in the branded and generic product lines 
the improvement in product mix in the specialty generic line was due primarily to higher margin new product sales 
lower costs in specialty generics were due to efficiencies from increased volume and lower prices for material and ingredients 
of the percentage point net decrease  changes in product mix accounted for  higher pricing accounted for and lower costs accounted for 
of the improvement 
research and development expenses increased million  or  compared to the prior year  due primarily to payments made in connection with product co development agreements and expansion of the research and development staff 
the company plans to continue its new product and technology development efforts and to rely on new products as an important part of its overall growth strategy 
selling and administrative expenses increased million  or  compared to the prior year 
the increase was due primarily to higher corporate administrative expenses  incremental marketing expenses in support of the specialty generics product line  and marketing expenses and continued investment in expanding the sales force for the branded products marketing division 
corporate administrative expenses were higher due to increases in payroll related expenses of million associated with expanding the company s management and administrative infrastructure to keep pace with its continued growth  higher professional fees of million for various legal and consulting services  and increased lease expense of million from the acquisition of a leased facility for future expansion of the company s distribution operations and administrative offices 
marketing expenses associated with the specialty generics product line were up million for the year  primarily due to promotional programs 
marketing and selling expenses associated with branded products were million higher compared to last year primarily due to expenses associated with the increase in the branded sales force and increased sampling costs in connection with the introduction of gynazole in the current fiscal year 
amortization expense is primarily attributed to the product acquisitions of micro k r and precare r 
these product acquisitions are being amortized on a straight line basis over years and there was no change when compared to the prior year 
operating income 
as a result of the factors described above  operating income increased million  or  compared to the prior year 
interest expense 
interest expense decreased 
million  or  for the year due to lower long term debt outstanding on the company s line of credit 
other income  decreased million for the year  due primarily to a non recurring gain related to an arbitration award of million received in fiscal and a decrease in interest income of 
million 
see note of notes to consolidated financial statements 
net income 
as a result of the factors described above  net income decreased 
million  or  compared to the prior year 
excluding the effect of the non recurring gain  net income increased million  or over the prior year 
fiscal compared to fiscal revenues 
net revenues for fiscal increased million  or  over the prior fiscal year 
the increase in revenues  after elimination of inter segment revenues  was due to higher sales in all three marketing divisions generic products  branded products and specialty materials as shown in the following table increase decrease vs prior year amount percent net revenues generic products  branded products  nm specialty materials  contract services licenses  total net revenues  branded product sales through ther rx in its first full marketing year grew to million versus million for the fourth quarter of fiscal year  when the business began operations 
this branded business was started by acquiring products with established brand name recognition and existing distribution  and through the subsequent introduction of internally developed products 
acquired products include micro k r extencaps acquired in march and the precare r prenatal caplet that was acquired in august ther rx also introduced three internally developed products since october under the precare r family of women s health care pharmaceuticals 
these products include precare r chewables  a chewable prenatal vitamin  premisisrx tm  a product designed for use along with a physician supervised program to reduce pregnancy related nausea  and precare r conceive tm  a nutritional supplement specifically designed for use by both men and women prior to conception 
of the million increase  or  in specialty generic net sales by ethex  volume increases in existing products and new products contributed million while million was from price increases 
ethex introduced seven new products during the year and in march  received anda approval for a generic alternative to imdur r by schering plough corporation 
specialty materials sales by particle dynamics increased by million  or  due primarily to higher volume in existing product lines on an expanded customer base 
contract services and licensing revenues decreased million  or  since the prior fiscal year included a million licensing payment and due to lower volume  reflecting a smaller customer base as the company de emphasized lower margin contract manufacturing in its business strategy 
while the company anticipates continued overall growth in sales of the products it markets  there are no assurances that the annual percentage rate of sales growth will continue at past levels 
costs and expenses 
manufacturing costs as a percentage of revenue declined from to due to the effects of favorable pricing and product mix 
the improvement in product mix reflected an increase in the relative contribution of higher margin brand sales and a decrease in lower margin generic pain management sales 
of the percentage point net decrease  changes in product mix and volume accounted for and pricing accounted for  which were offset by a increase in costs 
research and development expense increased million  or  compared to the prior year period 
the increase was due primarily to an increase in the number of clinical testing programs conducted 
the company expects to continue a high level of expenditures for research  clinical and regulatory efforts 
selling and administrative expenses increased million  or  compared to the corresponding period of the prior year 
the increase was due primarily to the company s investment in building the sales force for ther rx and related marketing expenses 
selling and marketing expenses associated with this effort were million 
selling and marketing expenses of ethex increased million 
amortization expense increased million due to the amortization of product rights acquired in march and august other income  net  decreased million to million during fiscal primarily due to a non recurring gain related to an arbitration award in fiscal  being million higher than the current year s award see note of notes to consolidated financial statements and net interest expense increasing million 
net income 
as a result of the factors described above  net income improved million  or  to million compared to the prior year period 
b regarding commodity prices the company utilizes various raw materials in its manufacturing processes 
although the company historically has not encountered material fluctuations in pricing of such commodities  there is no assurance that pricing of such commodities will remain relatively constant  and the company s manufacturing costs could increase significantly if raw material commodity prices increase by amounts substantially above current prices 
c variable rate risks advances to the company under the company s credit facility bear interest at a rate which varies consistent with increases or decreases in the publicly announced prime rate 
and or the libor rate with respect to libor related loans  if any 
a material increase in such rates  however  could significantly increase future borrowing expenses 
the company currently has no borrowings on its variable rate credit facility 
other long term debt consists primarily of fixed rate mortgage obligations 
d liquidity and capital resources the following table lists selected cashflow and balance sheet data for fiscal years  and in s cashflow from operations    working capital    long term liabilities    shareholders equity    see note a on page for non recurring gains and note of notes to consolidated financial statements 
cash flow from operations of million was million  or  lower than the prior year due primarily to the collection of a million arbitration award in the first quarter of last year 
excluding the effect of the non recurring award  cash from operations increased million  or  due primarily to a million reduction in cash used for working capital 
cash flow from operations for the fiscal year was due primarily to net income plus depreciation and amortization 
this was partially offset by increases in accounts receivable  inventories and prepaid expenses and a decrease in accounts payable and accrued liabilities 
the increase in accounts receivable was due to higher year end net receivables in the specialty generics division  primarily due to the timing of wholesaler purchases in the fourth quarter 
inventories increased primarily in raw materials to support increased production of specialty generic products 
the increase in prepaid expenses reflects user fees paid to the fda and product liability insurance prepayments 
the decrease in accounts payable and accrued liabilities was due to lower trade payables reflecting the timing of various material purchases 
long term liabilities decreased million in fiscal primarily as a result of a million payoff of borrowing incurred to finance the acquisition of the micro k r product line 
investing activities for fiscal were for capital expenditures of million 
capital expenditures were primarily for machinery and equipment for the upgrade and expansion of the company s pharmaceutical manufacturing and distribution facilities 
construction in progress at march  was estimated to cost million to complete 
the company plans to continue to invest in capital improvements in fiscal to include further upgrades and expansion of its manufacturing  laboratory and distribution facilities and expansion of its administrative offices to support expected growth 
the company believes that existing cash  cash generated from operating activities and funds available under its credit facility will be adequate to fund operating activities in the short and long term for the presently foreseeable future  including near and long term debt obligations  capital improvements  product development activities and expansion of marketing capabilities for the branded pharmaceutical business 
as of march   the company has a loan agreement expiring october with lasalle national bank 
the agreement provides for a revolving line of credit for borrowing up to million 
the company had no cash borrowing and million in open letters of credit issued under this facility 
ratios 
the following table lists selected financial ratios for the fiscal years  and working capital ratio to to to debt to equity 
to 
to 
to total liabilities to equity 
to 
to 
to the company s working capital ratio improved in fiscal due to an increase in current assets and a decrease in current liabilities 
the debt to equity and total liabilities to equity ratios improved due to the million decrease in long term debt associated with the pay off of borrowings from the credit facility incurred to finance the micro k r acquisition 
inflation 
although at reduced levels in recent years  inflation continues to apply upward pressure on the cost of goods and services used by the company 
however  the company believes that the net effect of inflation on its operations has been minimal during the past three years 
in addition  changes in the mix of products sold and the effect of competition has made a comparison of changes in selling prices less meaningful relative to changes in the overall rate of inflation over the past three years 
e new accounting standards in june  the fasb issued sfas no 
accounting for derivatives and hedging activities  which establishes accounting and reporting standards for derivative instruments  including certain derivative instruments embedded in other contracts collectively referred to as derivatives  and for hedging activities 
sfas no 
is effective for years beginning after june  and requires comparative information for all fiscal quarters of fiscal years beginning after june  the company does not expect the adoption of this statement to have a significant impact on its results of operations  financial position or cash flows 
in december  the sec released staff accounting bulletin sab no 
 revenue recognition in financial statements  providing the staff s views in applying accounting principles generally accepted in the united states to certain revenue recognition issues 
the company adopted sab no 
 as amended  in fiscal and there was no material effect on the company s consolidated financial position or results of operations 
item a 
quantitive and qualitive disclosures about market risk not applicable 

